RANDOMIZED DOUBLE-BLIND STUDY, PHASE III TO COMPARE TWO ALBENDAZOLE SCHEMES FOR THE TREATMENT OF RACEMOSA CISTICERCOSIS
Not Applicable
- Conditions
- -B690 Cysticercosis of central nervous systemCysticercosis of central nervous systemB690
- Registration Number
- PER-096-03
- Lead Sponsor
- IVERSIDAD PERUANA CAYETANO HEREDIA,
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
- Male or female individuals between 18-65 year of age with a diagnosed of basal subarachnoid cysticercosis (including locations in the Sylvian fissure) by neuroimaging and confirmed by serology.
- Willingness to accomplish the two weeks minimal hospitalization required.
Exclusion Criteria
- Previous therapy with albendazole or praziquantel.
- Pulmonary tuberculosis.
- Systemic disease other than neurocysticercosis that may affect therapy or short-term prognosis, including but not limited to chronic renal failurc, hepatic insufficiency, cardiac failure, and steroid-depcndent immune diseases.
- Patients in unstable condition or with severe intracranial hypertension (ICH).
- Pregnancy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <br>Outcome name:not contemplated<br><br>Measure:not contemplated<br><br>Timepoints:not contemplated<br>
- Secondary Outcome Measures
Name Time Method <br>Outcome name:not contemplated<br><br>Measure:not contemplated<br><br>Timepoints:not contemplated<br>